MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio

MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio MeMed BV test recently cleared for use by US FDA to aid in distinguishing between bacterial and

Related Keywords

Boston ,Massachusetts ,United States ,Phoenix ,Arizona ,Israel ,Kostenloser Wertpapierhandel ,Patrick Zhang ,Kfir Emmer ,Us Department Of Defense ,Caesara Medical Holdings ,Technology Investment ,Eu Commission ,Drug Administration ,Union Tech Ventures ,Consilium Strategic Communications ,Memed Key ,Horizons Ventures ,Shavit Capital ,Social Capital ,Touchwood Capital ,Clai Insurance ,Phoenix Insurance ,Poalim Equity ,Western Technology ,Med Contacts ,Will Harris ,Memed ,Raises ,Ccelerate ,Ommercialization ,Most ,Immune ,Response ,Product ,Portfolio ,